ImmuCell (ICCC) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ImmuCell (ICCC) has outperformed Telomir Pharmaceuticals (TELO) over the past year, gaining 48.0% versus a loss of 30.3%. ImmuCell is the larger company by market cap ($88.6 million vs $84.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCC | TELO |
|---|---|---|
| Share price | $9.75 | $1.15 |
| Market cap | $88.55M | $84.66M |
| 1-day change | +0.62% | +2.68% |
| YTD return | +58.54% | -13.53% |
| 1-year return | +47.95% | -30.30% |
| 5-year return | +5.06% | — |
| P/E ratio (TTM) | 139.29 | — |
| EPS (TTM) | $0.07 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.10 | $1.82 |
| 52-week low | $4.52 | $0.888 |
| Distance from 52-week high | -19.42% | -36.71% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +247.83% |
| Average volume | 22.20K | 97.98K |
| Shares outstanding | 9.08M | 73.62M |
| Employees | 73 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICCC has outperformed TELO by 78.3 percentage points over the past year.
About ImmuCell
ICCC stock →ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 73 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Health Care · Biotechnology: Pharmaceutical Preparations
ICCC vs TELO FAQ
Which is bigger, ImmuCell or Telomir Pharmaceuticals?
ImmuCell (ICCC) is larger, with a market capitalization of $88.55M compared with $84.66M for Telomir Pharmaceuticals (TELO).
Which stock has performed better over the past year, ICCC or TELO?
ICCC returned +47.95% over the past 12 months, compared with -30.30% for TELO (price return, excluding dividends). Past performance does not predict future results.
Are ImmuCell and Telomir Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for ImmuCell and Biotechnology: Pharmaceutical Preparations for Telomir Pharmaceuticals.